|
|
|
Reimagining Antibody Manufacturing
|
|
Many companies choose to manufacture mammalian cell culture-derived products using fed-batch technology. However, continuous manufacturing is more efficient than fed-batch manufacturing at the same production scale. Explore key considerations when choosing continuous bioprocessing and a continuous cell culture manufacturing platform.
|
|
|
|
|
CDMOs have focused on ways to overcome challenges customers face to meet their needs more effectively. Providing access to a well-established manufacturing network removes the risk of multiple tech transfers and third parties needed to achieve scale.
|
|
|
|
We aim to be the leading CDMO, setting the standard for sustainable operations. In this report, discover many of the concrete examples of the projects across our global network that are contributing to the successful achievement of our goals and aspirations.
|
|
|
|
By standardizing processes and using a flexible platform, KojoX™ de-risks the supply chain, accelerates time to market, and reduces costs. Review how to select the optimal manufacturing strategy and leverage technologies for efficient and scalable production of therapeutic proteins.
|
|
|
OUTSOURCED PHARMA CAPACITY UPDATE VIDEO FEATURE
|
|
|
|
Rasmus Pedersen, Ph.D., outlines strategies to expand large-molecule production capacity to meet the global medicine demand, noting the current gap that leaves two billion people without access.
|
|
|
|
Microbial CDMO Services
|
With over 30+ years’ of experience in microbial CDMO services, one of our core areas of expertise is the development of large-scale processes for recombinant protein expression in microbial hosts.
|
• Request Information
|
|
|
|
|
|